TG Therapeutics announced its Q1 2024 financial results, featuring $50.5 million in BRIUMVI U.S. net revenue, representing over 25% quarter-over-quarter growth. Total revenue reached $63.5 million, including a $12.5 million milestone payment. The company updated its full-year BRIUMVI U.S. net revenue guidance to $270 to $290 million.
BRIUMVI U.S. net revenue reached $50.5 million, exceeding expectations with over 25% quarter-over-quarter growth.
Total revenue for Q1 2024 was $63.5 million, including a $12.5 million milestone payment for BRIUMVI's EU launch.
Over 1,250 new BRIUMVI prescriptions were received by the TG hub, indicating strong demand.
Full-year BRIUMVI U.S. net revenue guidance was updated to $270 to $290 million.
TG Therapeutics anticipates continued growth for BRIUMVI and is focused on expanding its clinical development programs.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance